| Quarter (USD) | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 83.01 mm | 83.01 mm | 83.01 mm | 83.01 mm | 83.01 mm | 83.01 mm |
| Cash burn (monthly) | 6.36 mm | 1.29 mm | 18.35 mm | 16.41 mm | 12.21 mm | 12.11 mm |
| Cash used (since last report) | 24.29 mm | 4.91 mm | 70.07 mm | 62.67 mm | 46.62 mm | 46.24 mm |
| Cash remaining | 58.72 mm | 78.09 mm | 12.93 mm | 20.34 mm | 36.38 mm | 36.76 mm |
| Runway (months of cash) | 9.2 | 60.7 | 0.7 | 1.2 | 3.0 | 3.0 |
| 13F holders | Current |
|---|---|
| Total holders | 150 |
| Opened positions | 30 |
| Closed positions | 21 |
| Increased positions | 54 |
| Reduced positions | 36 |
| 13F shares | Current |
|---|---|
| Total value | 793.75 bn |
| Total shares | 84.71 mm |
| Total puts | 111.80 k |
| Total calls | 41.10 k |
| Total put/call ratio | 2.7 |
| Largest owners | Shares | Value |
|---|---|---|
| UBS Oncology Impact Fund | 7.91 mm | $234.17 mm |
| MPM Oncology Impact Management | 7.65 mm | $93.16 bn |
| Biotechnology Value Fund L P | 5.80 mm | $94.02 mm |
| BVF | 5.75 mm | $70.04 bn |
| BlackRock | 4.37 mm | $53.24 bn |
| Deerfield Management | 3.38 mm | $41.16 bn |
| Flynn James E | 3.28 mm | $59.31 mm |
| Vanguard | 2.94 mm | $35.76 bn |
| Citadel Advisors | 2.68 mm | $32.68 bn |
| Blue Owl Capital | 2.37 mm | $28.88 bn |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 25 Feb 25 | Jeffrey Alan Jones | Common Stock | Sell | Dispose S | No | No | 8.53 | 4,895 | 41.75 k | 174,164 |
| 25 Feb 25 | Nadim Ahmed | Common Stock | Sell | Dispose S | No | No | 8.53 | 12,529 | 106.87 k | 430,621 |
| 25 Feb 25 | Jennifer Michaelson | Common Stock | Sell | Dispose S | No | No | 8.53 | 3,756 | 32.04 k | 142,004 |
| 25 Feb 25 | Jacquelyn L Sumer | Common Stock | Sell | Dispose S | No | No | 8.53 | 3,756 | 32.04 k | 136,895 |
| 19 Feb 25 | Jennifer Michaelson | Common Stock | Grant | Acquire A | No | No | 0 | 50,000 | 0.00 | 145,760 |
| 19 Feb 25 | Jennifer Michaelson | Stock Option Common Stock | Grant | Acquire A | No | No | 9.43 | 100,000 | 943.00 k | 100,000 |
